bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.05.30.728992

Overexpression of Eaf1, a subunit of the NuA4 lysine acetyl transferase complex, rescues growth defects in the budding yeast H3K36M oncohistone model via histone H4 tail acetylation

Abstract

Histone proteins are critical for regulating nucleic acid transactions, including gene expression. Specific missense mutations in histone genes have been linked to oncogenesis, creating oncohistones. One of the first identified oncohistones converts K36 in histone H3 to M (H3K36M). While humans have 15 H3 genes, the Saccharomyces cerevisiae genome contains only two H3 genes. As H3 shares 90% sequence identity between budding yeast and humans, the budding yeast system provides an ideal model for study of H3K36M. We previously identified the catalytic subunit of the NuA4 lysine acetyltransferase complex as a high copy suppressor of growth defects in H3K36 mutant yeast cells. Here, we demonstrate that the NuA4 scaffold Eaf1 suppresses mutant H3K36 growth defects. We show that this suppression by Eaf1 is dependent on the Eaf1 HSA domain. To examine whether the role of NuA4 in acetylating histone H4 is required for suppression of H3K36 growth defects, we altered the four NuA4 target lysines within H4 (K5, 8, 12, and 16) to create quadruple histone mutants with all four of these lysines converted to alanine (H4-4K[->]A) or arginine (H4-4K[->]R). These H4 mutants have reduced viability and disrupted global H4 acetylation. Eaf1 cannot suppress growth defects in these H4 acetylation mutants, suggesting Eaf1-mediated suppression is dependent on acetylation of H4 N-terminal tails. We further show that inhibiting NuA4 activity in H3K36M human cells limits their oncogenic potential. Together, this work defines a mechanistic connection between H3K36 and H4 N-terminal tail acetylation in the context of a cancer-causing mutation. Article SummarySpecific mutations in histone genes have been found to cause various cancers, creating oncohistones, and the exact mechanisms by which they drive oncogenesis remain to be characterized. Budding yeast is a simple yet powerful model for studying oncohistones such as H3K36M. Subunits of the NuA4 lysine acetyltransferase complex were found to suppress growth defects in budding yeast expressing H3K36M. This suppression was dependent on the presence of the NuA4 target lysines in histone H4. Additionally, inhibiting NuA4 activity in human H3K36M cells limited their oncogenic potential. This work characterizes the mechanistic relationship between H3K36M and the NuA4 complex.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jones, C. Y., Chen, L., Fasken, M. B., Spangle, J. M., Corbett, A. H.. 2026-06-01. Overexpression of Eaf1, a subunit of the NuA4 lysine acetyl transferase complex, rescues growth defects in the budding yeast H3K36M oncohistone model via histone H4 tail acetylation. https://doi.org/10.64898/2026.05.30.728992

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Mechanism-selective deep mutational scanning distinguishes ERCC2 disease phenotypes

Pathogenic ERCC2 variants cause xeroderma pigmentosum (XP), trichothiodystrophy (TTD) or both, yet variant effect scores are usually interpreted only as measures of pathogenicity rather than of which disease mechanism is disrupted. XPD, the ERCC2-encoded TFIIH subunit, functions in both nucleotide excision repair and transcription. Using yeast complementation deep mutational scanning, we measured the effects of nearly all XPD amino acid substitutions. The assay was mechanism-selective: it preferentially reported transcription-associated function, with pronounced intolerance at the p44 interface, whereas many substitutions affecting DNA binding and helicase activity retained near-wild-type fitness. Accordingly, TTD variants had much lower fitness than XP variants. Computational predictors discriminated pathogenic from benign variants similarly across phenotypes, but the DMS distinguished XP from TTD variants better than all 73 predictors tested. Phenotype-specific ACMG/AMP calibration provided evidence in both directions for TTD but mainly pathogenic evidence for XP. Thus, the selectivity of functional assays, often viewed as a limitation, can reveal disease mechanisms and support phenotype-aware variant interpretation.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗